"10.1371_journal.pone.0114506","plos one","2014-12-12T00:00:00Z","Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; Franco Pandolfi; James T Kurnick","CytoCure LLC, Suite 430C, 100 Cummings Center, Beverly, MA, United States of America; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States of America; Department of Internal Medicine, Catholic University, Rome, Italy","Conceived and designed the experiments: TJH ISD LBR EEN FP JTK. Performed the experiments: TJH ISD LBR EEN JTK. Analyzed the data: TJH ISD LBR EEN JTK. Contributed reagents/materials/analysis tools: TJH ISD LBR JTK. Wrote the paper: TJH ISD LBR EEN JTK.","TJH, ISD, LBR, EEN & JTK are employed by CytoCure LLC, and JTK has equity rights to shares of CytoCure LLS. CytoCure LLC shares intellectual property rights with the General Hospital Corporation with respect to combination immunotherapy with Hsp90 inhibitors. Pending patent name: Methods, compositions, and kits for the treatment of cancer number: WO 2012166617 A2. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. The specific roles of these authors arearticulated in the ‘author contributions’ section.","2014","12","Timothy J Haggerty","TJH",6,TRUE,6,5,5,5,TRUE,TRUE,FALSE,0,NA,FALSE
